Jeff Albers, J.D., M.B.A.

Jeff Albers brings over 25 years of experience in the biopharmaceutical industry, bringing important new medicines to patients with cancer and rare diseases. He currently serves as board chairman at Blueprint Medicines, as board member at Kymera Therapeutics, MOMA Therapeutics, and Spyre Therapeutics, and board advisor for Life Sciences Cares. From 2014 to 2022, he served as Chief Executive Officer of Blueprint Medicines, where he transitioned the previously research-stage company through an initial public offering and into a leading precision medicine company with a global, fully integrated business, including multiple approved therapies and a rapidly advancing pipeline. He holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University.